Skip to main content
ASX:PAL

Palla Pharma Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive PAL News and Ratings via Email

Sign-up to receive the latest news and ratings for Palla Pharma and its competitors with MarketBeat's FREE daily newsletter.


About Palla Pharma

Palla Pharma Limited, a vertically integrated pharmaceutical company, produces and distributes narcotic raw materials, active pharmaceutical ingredients, and finished dosage formulations for pharmaceutical markets in Australia and Norway. It also produces and distributes poppy seeds to culinary markets. The company was formerly known as TPI Enterprises Limited and changed its name to Palla Pharma Limited in June 2019. Palla Pharma Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry Farm Products
Sub-IndustryN/A
CUSIPN/A
CIKN/A
Phone61 3 9301 0800
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$22.01 million
Book ValueA$0.29 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.33 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Palla Pharma (ASX:PAL) Frequently Asked Questions

What stocks does MarketBeat like better than Palla Pharma?

Wall Street analysts have given Palla Pharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Palla Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Palla Pharma's key executives?

Palla Pharma's management team includes the following people:
  • Mr. Brendan Middleton, Interim CEO & CFO
  • Mr. Jarrod David Ritchie B.Sc., BSc (Hons), Advisor
  • Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, GAICD, GradDip CSP, FGIA, Company Sec. (Age 57)

Who are some of Palla Pharma's key competitors?

What is Palla Pharma's stock symbol?

Palla Pharma trades on the ASX under the ticker symbol "PAL."

How much money does Palla Pharma make?

Palla Pharma has a market capitalization of $0.00 and generates $22.01 million in revenue each year.

What is Palla Pharma's official website?

The official website for Palla Pharma is www.pallapharma.com.

How can I contact Palla Pharma?

The company can be reached via phone at 61 3 9301 0800.


This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.